BRIEF-Advaxis Reports Q1 Loss Per Share $0.49
March 12, 2018 at 16:12 PM EDT
* ADVAXIS REPORTS FISCAL 2018 FIRST QUARTER FINANCIAL RESULTS AND ANNOUNCES CLINICAL HOLD IN AXALIMOGENE FILOLISBAC PHASE 1/2 COMBINATION STUDY WITH ASTRAZENECA’S IMFINZI® (DURVALUMAB)